Zhengping Zhuang
Zhengping Zhuang | |
|---|---|
| Alma mater | Shanghai Jiao Tong University School of Medicine (M.D.) Wayne State University (Ph.D.) |
| Known for | Cancer genetics, laser-capture microdissection, Pacak–Zhuang syndrome |
| Awards | Stowell–Orbison Award (1994) Gordon F. Vawter Award (1996) Federal Technology Transfer Awards (2018–2022) NIH APAO Outstanding Achievement Award (1999) Cy Katzen Humanitarian Award (2014) |
| Scientific career | |
| Fields | Molecular pathology, cancer genetics, translational oncology |
| Workplaces | National Cancer Institute, National Institutes of Health |
Zhengping Zhuang is an American physician-scientist and cancer researcher, widely recognized for his contributions to molecular pathology, cancer genetics, and translational oncology.[1] He is Senior Investigator at the Neuro-Oncology Branch of the National Cancer Institute (NCI), part of the National Institutes of Health (NIH).[2][3] His work has advanced fundamental understanding of cancer biology and has contributed to multiple therapeutic innovations.[4]
Education and training
Zhuang received his M.D. from Shanghai Jiao Tong University School of Medicine in 1983 and completed a residency in general surgery at Rui Jin Hospital.[5] He earned a Ph.D. in pharmacology from Wayne State University in 1990, followed by a postdoctoral fellowship at Harvard Medical School. He later completed residency training in transitional medicine at Henry Ford Hospital and in anatomic pathology at the NIH Laboratory of Pathology.[3]
Career
Zhuang joined the NIH in the early 1990s as a resident and subsequently served as staff pathologist at the NCI.[3] From 1999 to 2016, he was Head of the Molecular Pathogenesis Unit at the National Institute of Neurological Disorders and Stroke (NINDS). Since 2017, he has been Senior Investigator in the Neuro-Oncology Branch at the NCI.[2] He also holds an adjunct professorship at the Uniformed Services University of the Health Sciences.[3]
Research
Zhuang's research spans cancer genomics, hereditary tumor syndromes, immunotherapy, and therapeutic development. His work frequently bridges basic and translational science, with emphasis on central nervous system (CNS) tumors.[6]
Cancer genetics
Zhuang has contributed to the discovery and characterization of several cancer-associated genes, including:
- MEN1 (menin), the tumor suppressor gene mutated in multiple endocrine neoplasia type 1.[7]
- c-MET, a proto-oncogene mutated in Hereditary papillary renal carcinoma;[8]
- HIF2A (EPAS1), which causes a tumor-predisposition syndrome now known as Pacak–Zhuang syndrome;[9]
- SF3B1, associated with pituitary prolactinomas.[10]
He was also among the first to describe the cellular origins of tumors in Von Hippel–Lindau disease, showing that hemangioblast-derived lesions represent developmental angioblast arrest.[11]
Biotechnological innovation
Zhuang co-invented Laser capture microdissection (LCM), a method enabling isolation of specific cells from tissue samples.[12] Introduced in 1996, LCM remains widely used in molecular and cellular research.[13] He has also developed genomic and proteomic profiling approaches for CNS tumors, identifying stem cell–like tumor subpopulations and aberrant β-catenin signaling.[6]
Therapeutic development
Zhuang has advanced novel therapeutic approaches, including enhancing proliferative pathways in combination with DNA-damaging therapy. He co-developed LB100, a small-molecule PP2A inhibitor that sensitizes tumors to chemotherapy, radiotherapy, and immunotherapy.[14] LB100 entered FDA-approved clinical trials and has shown early efficacy.[4]
He has also developed a whole-tumor cell cancer vaccine (rWTC-MBTA), which activates dendritic cells and targets metastatic disease.[15]
Selected publications
- Emmert-Buck, MR; Bonner RF; Smith PD; Zhuang Z (1996). "Laser capture microdissection". Science. 274 (5289): 998–1001. Bibcode:1996Sci...274..998E. doi:10.1126/science.274.5289.998. PMID 8875945.
- Schmidt, L; Duh F-M; Chen F; Zhuang Z (1997). "Germline mutations in the MET proto-oncogene in hereditary papillary renal carcinoma". Nature Genetics. 16 (1): 68–73. doi:10.1038/ng0597-68. PMID 9140397.
- Zhuang, Z; Yang C; Cao L (2012). "Somatic mutations in EPAS1 in patients with paraganglioma and polycythemia". New England Journal of Medicine. 367 (10): 922–930. doi:10.1056/NEJMoa1205119. PMC 3432945. PMID 22931260.
- Li, C; Xie W; Zhuang Z (2020). "Somatic SF3B1 hotspot mutation in prolactinomas". Nature Communications. 11 (1) 2506. Bibcode:2020NatCo..11.2506L. doi:10.1038/s41467-020-16052-8. PMC 7253411. PMID 32461610.
- Wang, H; Zhuang Z; Pacak K (2022). "Somatic mosaicism of EPAS1 mutations in Pacak-Zhuang syndrome". Endocrine Practice. 28 (6): 576–584. doi:10.1016/j.eprac.2022.04.012. PMC 9271630. PMID 35489703.
- Ho, WS; Wang H; Zhuang Z (2018). "Pharmacologic inhibition of protein phosphatase-2A achieves durable immune-mediated antitumor activity when combined with PD-1 blockade". Nature Communications. 9 (1): 381–383. Bibcode:2018NatCo...9.2126H. doi:10.1038/s41467-018-04425-z. PMC 5974350. PMID 29844594.
- Wang, H; Pacak K; Zhuang Z (2024). "rWTC-MBTA Vaccine Induces Potent Adaptive Immune Responses Against Glioblastomas via Dynamic Activation of Dendritic Cells". Advanced Science. 11 (14) e2308280. Bibcode:2024AdvSc..1108280W. doi:10.1002/advs.202308280. PMC 11005728. PMID 38298111.
Awards and honors
- Stowell–Orbison Award, USCAP (1994)[3]
- Gordon F. Vawter Award, Society for Pediatric Pathology (1996)[3]
- NIH APAO Outstanding Achievement Award (1999)[3]
- Cy Katzen Humanitarian Award (2014)[4]
- Federal Technology Transfer Awards (2018, 2019, 2020, 2022)[4]
- NCI New Invention and Technology Development Award (1995, 2019)[13]
References
- ↑ "Colleagues: Recently Tenured | NIH Intramural Research Program". irp.nih.gov.
- 1 2 "Zhengping Zhuang, M.D., Ph.D." National Cancer Institute. Retrieved August 20, 2025.
- 1 2 3 4 5 6 7 "Zhengping Zhuang". NIH Intramural Research Program. Archived from the original on June 23, 2025. Retrieved August 20, 2025.
- 1 2 3 4 "Celebrating CCR Careers: Zhengping Zhuang, M.D., Ph.D." NCI Center for Cancer Research. July 2023. Retrieved August 20, 2025.
- ↑ "Zhengping Zhuang, M.D., Ph.D. | Center for Cancer Research". ccr.cancer.gov.
- 1 2 "Zhengping Zhuang, M.D., Ph.D.: Investigation of Hypoxia HIF-2 Alpha Signaling in Tumorigenesis and Development of Therapeutics". First Faculty of Medicine, Charles University. Retrieved August 20, 2025.
- ↑ Chandrasekharappa, SC; Guru SC; Manickam P (1997). "Identification of the MEN1 gene responsible for multiple endocrine neoplasia type 1". Science. 276 (5311): 404–407. doi:10.1126/science.276.5311.404. PMID 9103196.
- ↑ Schmidt, L; Duh F-M; Chen F; Zhuang Z (1997). "Germline mutations in the MET proto-oncogene in hereditary papillary renal carcinoma". Nature Genetics. 16 (1): 68–73. doi:10.1038/ng0597-68. PMID 9140397.
- ↑ Zhuang, Z; Yang C; Cao L (2012). "Somatic mutations in EPAS1 in patients with paraganglioma and polycythemia". New England Journal of Medicine. 367 (10): 922–930. doi:10.1056/NEJMoa1205119. PMC 3432945. PMID 22931260.
- ↑ Li, C; Xie W; Zhuang Z (2020). "Somatic SF3B1 hotspot mutation in prolactinomas". Nature Communications. 11 (1) 2506. Bibcode:2020NatCo..11.2506L. doi:10.1038/s41467-020-16052-8. PMC 7253411. PMID 32461610.
- ↑ Vortmeyer, A. O.; Frank, S.; Jeong, S. Y.; Yuan, K.; Ikejiri, B.; Lee, Y. S.; Bhowmick, D.; Lonser, R. R.; Smith, R.; Rodgers, G.; Oldfield, E. H.; Zhuang, Z. (2003). "Developmental arrest of angioblastic lineage initiates tumorigenesis in von Hippel-Lindau disease". Cancer Research. 63 (21): 7051–7055. PMID 14612494.
- ↑ Emmert-Buck, MR; Bonner RF; Smith PD; Zhuang Z (1996). "Laser capture microdissection". Science. 274 (5289): 998–1001. Bibcode:1996Sci...274..998E. doi:10.1126/science.274.5289.998. PMID 8875945.
- 1 2 "Dissecting good from bad with laser capture". NIH Intramural Research Program. Retrieved August 20, 2025.
- ↑ Lu, J; Zhuang Z; Hunter T (2009). "LB-100 enhances the effectiveness of DNA damage anti-cancer drugs against cancer cells showing multi-drug resistance". Proceedings of the National Academy of Sciences. 106 (8): 3053–3058. doi:10.1073/pnas.0813345106. PMC 2651347. PMID 19223580.
- ↑ Wang, H; Pacak K; Zhuang Z (2024). "rWTC-MBTA Vaccine Induces Potent Adaptive Immune Responses Against Glioblastomas via Dynamic Activation of Dendritic Cells". Advanced Science. 11 (14) e2308280. Bibcode:2024AdvSc..1108280W. doi:10.1002/advs.202308280. PMC 11005728. PMID 38298111.